The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19

• DOI: 10.1007/s10557-020-07133-3
• Publication Date: 2021-01-04T07:03:15Z
• Authors: Lan Shen; Lin Qiu; Dong Liu; Li Wang; Hengye Huang; Heng Ge; Ying Xiao; Yi Liu; Jingjin Jin; Xiulan Liu; Dao Wen Wang; Eric D. Peterson; Ben He; Ning Zhou
• Keywords: 2019-20 coronavirus outbreak; Betacoronavirus

To determine the association between low molecular weight heparin (LMWH) use and mortality in hospitalized COVID-19 patients. We conducted a retrospective study of patients consecutively enrolled from two major academic hospitals exclusively for Wuhan, China, January 26, 2020, to March 2020. The primary outcome was adjusted in-hospital LMWH group compared with non-LMWH using propensity score. Overall, 525 median age 64 years (IQR 19), 49.33% men. Among these, 120 (22.86%) were treated LMWH. Compared group, more likely be older male; had history hypertension, diabetes, coronary heart disease (CHD), or stroke; severe parameters such as higher inflammatory cytokines D-dimer. unadjusted rate (21.70% vs. 11.10%; p = 0.004), but lower risk (adjusted odds ratio [OR], 0.20; 95% CI, 0.09–0.46). A score-weighting analysis demonstrated similar findings OR, 0.18; 0.10–0.30). Subgroup showed significant survival benefit among those who severely 0.07; 0.02–0.23) critically ill 0.32; 0.15–0.65), well elderly patients' > 65, IL-6 10 times upper limit level, D-dimer 5 level. patients, associated all-cause than users. particularly